Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

<p>– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progression free survival in mCRPC patients with tumors harboring AR 878/875 mutations – – Interim data from the Phase 1/2 trial of Arvinas’ second PROTAC AR degrader, ARV-766, showed robust efficacy in a broader mCRPC […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/potential-of-arvinas-protac-ar-degraders-reinforced-by-11-1-months-rpfs-with-bavdegalutamide-and-updated-positive-interim-data-from-second-generation-arv-766-in-mcrpc/">Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>